Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
328 stopped studies mapped to Myelodysplastic Syndrome and descendants · 88% state a reason
Over the 328 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00589316 | Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body… | Phase 1 | terminated | Jan 9, 2008 | Fred Hutchinson Cancer Center | Terminated due to loss of funding | Funding |
| NCT05223699 | Study of MGTA-117 in Patients With Adult Acute Myeloid Leukemia (AML) and… | Phase 1 | terminated | Feb 4, 2022 | Magenta Therapeutics, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT04095858 | Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease…(CATHY) | Phase 3 | terminated | Sep 19, 2019 | Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Business Reasons | Sponsor / business decision |
| NCT00003407 | Amifostine & High-Dose Combination Chemotherapy in Treating Patients With Acute ML or CML | Phase 2 | withdrawn | Apr 27, 2004 | Rush University Medical Center | The P.I deceased. | Other (stated, no rule matched) |
| NCT01028716 | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic… | Phase 2 | terminated | Dec 9, 2009 | Fred Hutchinson Cancer Center | The study experienced lower accrual rates after the onset of COVID. Upon review of the collected… | COVID-19 / pandemic |
| NCT00119366 | Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and… | Phase 2 | terminated | Jul 13, 2005 | Fred Hutchinson Cancer Center | Funding ended before target accrual was reached; participants are no longer being examined or… | Enrollment / accrual |
| NCT04866056 | Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF. | Phase 1 / Phase 2 | terminated | Apr 29, 2021 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Corporate policy adjustments | Other (stated, no rule matched) |
| NCT05246384 | Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in… | Phase 1 / Phase 2 | withdrawn | Feb 18, 2022 | Rhizen Pharmaceuticals SA | Change in development plan | Other (stated, no rule matched) |
| NCT01773395 | GVAX vs. Placebo for MDS/AML After Allo HSCT | Phase 2 | terminated | Jan 23, 2013 | Dana-Farber Cancer Institute | Recommendation by the Data and Safety Monitoring Board due to efficacy concerns | Safety / toxicity |
| NCT02452983 | Sertraline in Treatment of Low-Risk Myelodysplastic Syndrome(SS1) | Phase 1 | terminated | May 25, 2015 | Gustavo Rivero | This protocol is closed to further enrollment due to lack of study progress. | Enrollment / accrual |
| NCT02999854 | Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation…(HATCY) | Phase 3 | terminated | Dec 21, 2016 | Kiadis Pharma | Insufficient efficacy, terminated by Sponsor | Efficacy / futility |
| NCT04264806 | A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in… | Phase 2 | withdrawn | Feb 11, 2020 | Janssen Research & Development, LLC | The cusatuzumab MDS strategy is under revision | Sponsor / business decision |
| NCT00968864 | T-cell Depleted Alternative Donor Transplantation | Phase 2 | terminated | Aug 31, 2009 | Wake Forest University Health Sciences | Sponsor/ PI leaving institution, no plans to continue this research at this time | Other (stated, no rule matched) |
| NCT03600909 | A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients… | Phase 2 | terminated | Jul 26, 2018 | Memorial Sloan Kettering Cancer Center | Accrual has been slow | Enrollment / accrual |
| NCT04893915 | Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS | Phase 2 | withdrawn | May 20, 2021 | Washington University School of Medicine | No funding support | Funding |
| NCT03696537 | IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT | Phase 1 | terminated | Oct 4, 2018 | Naoyuki G. Saito, M.D., Ph.D. | Extreme toxicity | Safety / toxicity |
| NCT04331483 | A Study to Assess a Physical Activity Program in Children, Adolescents and Young Adults…(EVAADE) | N/A | withdrawn | Apr 2, 2020 | Centre Leon Berard | modification of the intervention before patient's enrollment, new protocol submitted | Enrollment / accrual |
| NCT04044209 | A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade… | Phase 2 | withdrawn | Aug 5, 2019 | Yale University | No patients were able to be screened nor enrolled. | Enrollment / accrual |
| NCT00740181 | Decitabine, Cytarabine, GCSF for Refractory AML/MDS | Phase 2 | terminated | Aug 22, 2008 | Brown University | Lack of efficacy | Efficacy / futility |
| NCT02795520 | Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute… | Phase 1 / Phase 2 | terminated | Jun 10, 2016 | OncoTherapy Science, Inc. | slow patient accrual | Enrollment / accrual |
| NCT02319369 | Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine… | Phase 1 | terminated | Dec 18, 2014 | Daiichi Sankyo | This study was terminated based on a business decision by the Sponsor. | Sponsor / business decision |
| NCT03588936 | Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant | Phase 1 | terminated | Jul 17, 2018 | Medical College of Wisconsin | Poor accrual and loss of funding. | Enrollment / accrual |
| NCT04464889 | HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem… | Phase 1 | withdrawn | Jul 9, 2020 | Medigene AG | Medigene transfered all rights to a new Sponsor | Other (stated, no rule matched) |
| NCT00900120 | Collecting and Storing Blood Samples From Patients With Cancer | — | withdrawn | May 12, 2009 | University of Medicine and Dentistry of New Jersey | Will be replaced by honest broker program | Other (stated, no rule matched) |
| NCT01045382 | MSC and HSC Coinfusion in Mismatched Minitransplants | Phase 2 | terminated | Jan 11, 2010 | University of Liege | recruitment too slow | Enrollment / accrual |
| NCT01663766 | Phase I Study of Milatuzumab for Graft Versus Host Disease | Phase 1 | terminated | Aug 13, 2012 | Gilead Sciences | PIs agreed no safety signals were shown, drug did not appear to lessen the risk of preventing GVHD… | Safety / toxicity |
| NCT04217720 | SNS-301 Monotherapy in High Risk MDS and CMML | Phase 2 | withdrawn | Jan 3, 2020 | Sensei Biotherapeutics, Inc. | Sponsor decision | Sponsor / business decision |
| NCT04296214 | Pharmacoeconomics in the Application of 5-azacitidine in the Treatment of Myelodysplastic… | — | withdrawn | Mar 5, 2020 | Grupo Cooperativo de Hemopatías Malignas | Poor recruitment | Enrollment / accrual |
| NCT03602898 | Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate… | Phase 2 | withdrawn | Jul 27, 2018 | Fred Hutchinson Cancer Center | Insufficient funding | Funding |
| NCT04395092 | Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and… | Phase 2 | withdrawn | May 20, 2020 | Kiadis Pharma | The sponsor decided to withdraw this study | Sponsor / business decision |
| NCT00967343 | Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host… | Phase 2 / Phase 3 | terminated | Aug 27, 2009 | Kiadis Pharma | not stated | Not stated |
| NCT03066466 | Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD… | Phase 3 | withdrawn | Feb 28, 2017 | Loyola University | No participants were enrolled | Enrollment / accrual |
| NCT01685411 | Busulfan and Cyclophosphamide Followed By ALLO BMT | N/A | terminated | Sep 14, 2012 | Masonic Cancer Center, University of Minnesota | not stated | Not stated |
| NCT02648932 | The Rapid Study: Randomized Phase II Study To Expedite Allogeneic Transplant With… | Phase 2 | terminated | Jan 7, 2016 | University of Chicago | Poor accrual | Enrollment / accrual |
| NCT03113071 | Safety and Activity of Digoxin With Decitabine in Adult AML and MDS | Phase 1 / Phase 2 | terminated | Apr 13, 2017 | Fox Chase Cancer Center | Slow accrual | Enrollment / accrual |
| NCT00176930 | Stem Cell Transplant for Hematological Malignancy | N/A | terminated | Sep 15, 2005 | Masonic Cancer Center, University of Minnesota | replaced by another study ; Trial re-written as MT2015-29 | Other (stated, no rule matched) |
| NCT01643603 | Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic… | Phase 1 | terminated | Jul 18, 2012 | Barbara Ann Karmanos Cancer Institute | Study terminated due to slow accrual. | Enrollment / accrual |
| NCT01300611 | TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation(USBTXA127CBT) | Phase 1 | terminated | Feb 21, 2011 | Tarix Pharmaceuticals | not stated | Not stated |
| NCT02750254 | Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation | Phase 1 | terminated | Apr 25, 2016 | Washington University School of Medicine | Toxicity. Only enrolled patients in phase I portion of trial. | Safety / toxicity |
| NCT03027401 | Clinical Sequencing of Cancer and Tissue Repository: OncoGenomics | — | withdrawn | Jan 23, 2017 | National Cancer Institute (NCI) | closed by PI and FDA | Other (stated, no rule matched) |
| NCT00020969 | Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes | Phase 2 | terminated | Jan 27, 2003 | CTI BioPharma | not stated | Not stated |
| NCT02786485 | Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After… | Phase 1 | withdrawn | Jun 1, 2016 | Bellicum Pharmaceuticals | not stated | Not stated |
| NCT02991898 | Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies | Phase 2 | terminated | Dec 14, 2016 | Masonic Cancer Center, University of Minnesota | Considering new technology for product. | Other (stated, no rule matched) |
| NCT00506948 | Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute… | Phase 2 | terminated | Jul 25, 2007 | M.D. Anderson Cancer Center | Halted due to high incidence of veno-oclusive disease of the liver. | Other (stated, no rule matched) |
| NCT00726830 | Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer | N/A | terminated | Aug 1, 2008 | M.D. Anderson Cancer Center | Low Accrual. | Enrollment / accrual |
| NCT00914940 | Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts… | Phase 2 | terminated | Jun 5, 2009 | Fred Hutchinson Cancer Center | Did not reach one of the primary endpoints of decreased total acute GVHD | Other (stated, no rule matched) |
| NCT00674427 | Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After… | Phase 1 | terminated | May 7, 2008 | University of Pennsylvania | Insufficient funds | Funding |
| NCT03807063 | Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood… | Phase 1 | withdrawn | Jan 16, 2019 | Fred Hutchinson Cancer Center | Insufficient funding | Funding |
| NCT00004114 | Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced… | Phase 1 | withdrawn | Feb 16, 2004 | Jonsson Comprehensive Cancer Center | Study never opened | Other (stated, no rule matched) |
| NCT00234000 | Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes | Phase 1 | terminated | Oct 6, 2005 | Jonsson Comprehensive Cancer Center | The study was closed due to poor enrollment | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Feb 9, 2023source: clinicaltrials